Nystatin dihydrate CAS:1400-61-9 Nystatin A1 >85%; any other compounds
| Catalog Number | XD90352 |
| Product Name | Nystatin dihydrate |
| CAS | 1400-61-9 |
| Molecular Formula | C47H75NO17 · 2H2O |
| Molecular Weight | 962.10 |
| Storage Details | -15 to -20 °C |
| Harmonized Tariff Code | 29419000 |
Product Specification
| Conclusion | Conforms to Ph.Eur. 9.7 |
| Pseudomonas aeruginosa | Absent |
| pH | 6.0-8.0 (3% aqueous solution) |
| Assay | Nystatin A1 >85%; any other compounds <4% |
| Loss on Drying | <5.0% |
| Appearance | Yellow or brown yellow powder |
| Sulfated ash | <3.5% |
| I.D. Test D | Conforms (UV) |
| TAMC | <1000cfu/g |
| TYMC | <100cfu/g |
| Staphylococcus Aureus | Absent |
| Residual Solvent Methanol | <3000ppm |
| Mesityloxide | <500ppm |
| Residual Solvent | <5000ppm |
| Identification (U.V.) Test A | identical with reference |
| Absorbance A305 | >0.6 |
| bile-tolerant gram-negative bacteria (E.coli + Salmonella sp.) | Absent |
| Clostridia species | Absent |
| Residual Solvents (1-butanol) | <1000ppm |
| Purity;Microbial Assay | NLT >4400 I.U./mg on dried basis |
To determine clinical variables to distinguish invasive pulmonary aspergillosis (IPA) from colonization in patients with chronic pneumopathies with positive culture of Aspergillus spp. in respiratory samples.Retrospective cohort study including patients with respiratory isolations of Aspergillus spp. during a period of 10 years. IPA was evaluated according to the Bulpa criteria. Clinical variables were collected and a multiple logistic regression analysis was carried out.Eighty-three patients with isolation of Aspergillus spp. from respiratory samples were included; 68.7% (n=57) of the patients had chronic obstructive pulmonary disease, 18% (n=15) pulmonary fibrosis and 13.3% (n=11) bronchial asthma. Twenty-two patients (26.6%) had IPA. The use of fluconazole (OR 4.49; CI 95% 1.5-13.4; P=.007), severe respiratory failure (OR 4.64; CI 95% 1.46-14.72; P=.009) and hospitalization time (OR 1.05; CI 95% 1.01-1.1; P=.006) were associated with IPA.Prior use of fluconazole, severe respiratory failure and hospitalization time are associated with IPA in patients with chronic pneumopathies with respiratory isolation of Aspergillus spp.Copyright © 2012 Elsevier España, S.L. All rights reserved
